Hepatic Arterial Infusion Chemotherapy Combined with Toripalimab and Surufatinib for the Treatment of Advanced Intrahepatic Cholangiocarcinoma

Overview

Journal Diagn Interv Radiol

Publisher Galenos Publishing House

Date 2024 Jun 5

PMID 38836437

Authors

Songlin Song

Yiming Liu

Yanqiao Ren

Chuansheng Zheng

Bin Liang

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of the present study is to report the clinical results of patients with advanced intrahepatic cholangiocarcinoma (ICC) who received combination therapy of hepatic arterial infusion chemotherapy (HAIC), toripalimab and surufatinib.

Methods: The study cohort consisted of 28 patients with advanced ICC who were treated with HAIC (mFOLFOX6 regimen, Q3W) in combination with intravenous toripalimab (240 mg, Q3W) and oral surufatinib (150 mg, once daily). The cohort had 14 male and 14 female patients. The baseline characteristics of the study cohort were obtained. The tumor response and drug-associated toxicity were assessed and reported.

Results: During the follow-up period (median follow-up time: 11.3 months; range: 4-19 months), four patients died of tumor progression. The objective response rate and disease control rate were 58% and 79%, respectively. The mPFS was 9.5 months, and the overall survival rate was 83.3%. The most frequent adverse events were nausea and vomiting (100%) and abdominal pain (85.7%). Serious complications related to death were not observed.

Conclusion: The combination treatment schedule for advanced ICC demonstrated positive efficacy and safety profiles.

Clinical Significance: This study provides promising clinical guidance for the treatment of advanced cholangiocarcinoma and is expected to modify the treatment strategy for this disease.

References

Fu J, Wang F, Dong L, Deng C, Wang X, Xie X . Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody. Acta Pharmacol Sin. 2017; 38(5):710-718. PMC: 5457696. DOI: 10.1038/aps.2016.161. View

Wang Y, Wei Z, Zhang Z, Xu J, Wang Y, Chen Q . Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study. Hepat Oncol. 2023; 10(2):HEP49. PMC: 10577516. DOI: 10.2217/hep-2023-0006. View

Gerber D, Schiller J . Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol. 2013; 31(8):1009-20. PMC: 3589699. DOI: 10.1200/JCO.2012.43.7459. View

Javle M, Lowery M, Shroff R, Weiss K, Springfeld C, Borad M . Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2017; 36(3):276-282. PMC: 6075847. DOI: 10.1200/JCO.2017.75.5009. View

Rogers J, Law L, Nguyen V, Qiao W, Javle M, Kaseb A . Second-line systemic treatment for advanced cholangiocarcinoma. J Gastrointest Oncol. 2014; 5(6):408-13. PMC: 4226829. DOI: 10.3978/j.issn.2078-6891.2014.072. View

Yao K, Jabbour S, Parekh N, Lin Y, Moss R . Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database. BMC Gastroenterol. 2016; 16(1):117. PMC: 5031355. DOI: 10.1186/s12876-016-0527-z. View

Irie T . Intraarterial chemotherapy of liver metastases: implantation of a microcatheter-port system with use of modified fixed catheter tip technique. J Vasc Interv Radiol. 2001; 12(10):1215-8. DOI: 10.1016/s1051-0443(07)61682-0. View

Keam S . Toripalimab: First Global Approval. Drugs. 2019; 79(5):573-578. DOI: 10.1007/s40265-019-01076-2. View

Huang Y, Du Z, Kan A, He M, Li H, Lai Z . Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma. Front Immunol. 2024; 15:1260191. PMC: 10880187. DOI: 10.3389/fimmu.2024.1260191. View

10.

Tang B, Yan X, Sheng X, Si L, Cui C, Kong Y . Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. J Hematol Oncol. 2019; 12(1):7. PMC: 6332582. DOI: 10.1186/s13045-018-0693-2. View

11.

Shi G, Huang X, Wu D, Sun H, Liang F, Ji Y . Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study. Signal Transduct Target Ther. 2023; 8(1):106. PMC: 10020443. DOI: 10.1038/s41392-023-01317-7. View

12.

Li Q, He M, Chen H, Fang W, Zhou Y, Xu L . Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J Clin Oncol. 2021; 40(2):150-160. DOI: 10.1200/JCO.21.00608. View

13.

Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S . Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2007; 98(2):418-25. PMC: 2361442. DOI: 10.1038/sj.bjc.6604129. View

14.

Brown D, Cardella J, Sacks D, Goldberg S, Gervais D, Rajan D . Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol. 2006; 17(2 Pt 1):225-32. DOI: 10.1097/01.RVI.0000195330.47954.48. View

15.

Oh D, He A, Qin S, Chen L, Okusaka T, Vogel A . Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2024; 1(8):EVIDoa2200015. DOI: 10.1056/EVIDoa2200015. View

16.

Kelley R, Ueno M, Yoo C, Finn R, Furuse J, Ren Z . Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 401(10391):1853-1865. DOI: 10.1016/S0140-6736(23)00727-4. View

17.

Vexler A, Mou X, Gabizon A, Gorodetsky R . Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies. Int J Cancer. 1995; 60(5):611-5. DOI: 10.1002/ijc.2910600507. View

18.

Raderer M, Hejna M, Valencak J, Kornek G, Weinlander G, Bareck E . Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology. 1999; 56(3):177-80. DOI: 10.1159/000011961. View

19.

Xu J, Bai Y, Sun H, Bai C, Jia R, Li Y . A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer. Cancer. 2021; 127(21):3975-3984. DOI: 10.1002/cncr.33803. View

20.

Yang Z, Fu Y, Wu W, Hu Z, Pan Y, Wang J . Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma. Front Pharmacol. 2023; 14:1234342. PMC: 10508288. DOI: 10.3389/fphar.2023.1234342. View